WBDE(SZ:002082)2022-11-15 23:11Company Overview - The company has undergone a transformation from traditional aluminum processing and non-ferrous metal trading to a focus on pharmaceutical manufacturing and medical devices since 2017 [1] - Wanbangde Pharmaceutical Group is a high-tech enterprise specializing in the R&D, production, and sales of modern Chinese medicine, chemical raw materials, and their formulations [1] - The company has a diverse product portfolio, particularly in cardiovascular and neurological medications, and is one of the domestic leaders in terms of drug types and approvals [1] Core Products - The core product, Ginkgo Biloba Drop Pills, is based on German standards and has independent intellectual property rights, classified as a national secondary protected Chinese medicine [1] - The company has developed the first-in-class drug Huperzine A, which has received patents in China, the US, Japan, and the EU [2] - The injection of Huperzine A was successfully launched in 2018, with ongoing clinical trials for controlled-release tablets [2] Market Position and Sales - Ginkgo Biloba Drop Pills hold approximately 18% market share in domestic medical institutions, with a market size of around 3 billion [2] - The sales of Huperzine A injection were about 100 million in 2021, with an expected increase to 160,000 units this year [3] - The company aims to cover 1,000 top-tier hospitals in the next three years as part of its national sales network expansion [3] Future Plans - By 2025, the company plans to achieve an annual output value of 5 billion across its three main production bases: raw materials, formulations, and medical devices [3] - The revenue composition is expected to be approximately one-third from traditional Chinese medicine, chemical medicine, and medical devices [3] - The company is focusing on international market expansion, particularly in the raw materials sector, while maintaining a strong domestic presence [3]